Jordan - engleski - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة أدوية الحكمة - hikma pharmaceuticals - cefixime 400 mg - 400 mg

Jordan - engleski - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة أدوية الحكمة - hikma pharmaceuticals - cefixime 400 mg - 400 mg

Australija - engleski - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amisulpride, quantity: 400 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hypromellose; sodium starch glycollate type a; magnesium stearate; lactose monohydrate; titanium dioxide; macrogol 400 - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

luye pharma australia pty ltd - quetiapine fumarate, quantity: 460.5 mg (equivalent: quetiapine, qty 400 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium citrate dihydrate; hypromellose; magnesium stearate; macrogol 400; titanium dioxide - seroquel xr is indicated for: bipolar disorder - maintenance treatment of bipolar 1 disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes. treatment of depressive episodes associated with bipolar disorder (see dosage and administration). treatment of acute mania associated with bipolar i disorder as monotherapy or incombination with lithium or sodium valproate. efficacy of seroquel xr in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of seroquel. schizophrenia - treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy. major depressive disorder (mdd)- treatment of recurrent major depressive disorder in patients who are intolerant of, or who have an inadequate response to alternative therapies. generalised anxiety disorder (gad). treatment of generalised anxiety disorder.

Jordan - engleski - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - carbamazepine 400 mg - 400 mg

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - amisulpride 400mg;  ;   - tablet - 400 mg - active: amisulpride 400mg     excipient: hypromellose   lactose monohydrate macrogol stearate 2000 magnesium stearate microcrystalline cellulose powdered cellulose sodium starch glycolate titanium dioxide

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

reckitt benckiser (new zealand) limited - ibuprofen 400mg;   - liquid filled capsule - 400 mg - active: ibuprofen 400mg   excipient: gelatin ribbon print solvent lecithin macrogol 600 medium-chain triglycerides opacode white nsp-78-18022 ponceau 4r potassium hydroxide purified water sorbitol

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

reckitt benckiser (new zealand) limited - ibuprofen lysine 684mg equivalent to 400 mg ibuprofen;   - film coated tablet - 400 mg - active: ibuprofen lysine 684mg equivalent to 400 mg ibuprofen   excipient: hypromellose magnesium stearate opacode black s-1-277001 opaspray white m-1-7111b povidone purified talc sodium starch glycolate

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - teicoplanin 400mg - powder for injection with diluent - 400 mg - active: teicoplanin 400mg excipient: sodium chloride sodium hydroxide water for injection

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - belimumab 400mg - powder for injection - 400 mg - active: belimumab 400mg excipient: citric acid monohydrate polysorbate 80 sodium citrate dihydrate sucrose - benlysta is indicated as add-on therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus (sle) with a high degree of disease activity (e.g. ana titre > 1:80 and/or anti-dsdna titre > 30 iu/ml) despite standard therapy. the safety & efficacy of benlysta have not been evaluated in patients with severe active lupus nephritis or severe active cns lupus.